|
|
Additional Information About The Proposed Transaction And Where To Find It
In connection with the proposed transaction between Rentokil Initial plc (“Rentokil”) and Terminix Global Holdings, Inc. (“Terminix”), Rentokil will
file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4, which will include a proxy statement of
Terminix that also constitutes a prospectus of Rentokil. Each of Rentokil and Terminix will also file other relevant documents in connection with the
proposed transaction. The definitive proxy statement/prospectus will be sent to the shareholders of Terminix. Rentokil will also file a shareholder
proxy circular in connection with the proposed transaction with applicable securities regulators in the United Kingdom and the shareholder
proxy circular will be sent to Rentokil’s shareholders. This communication is not a substitute for any registration statement, proxy statement/
prospectus or other documents Rentokil and/or Terminix may file with the SEC in connection with the proposed transaction. BEFORE MAKING
ANY VOTING OR INVESTMENT DECISIONS, INVESTORS, STOCKHOLDERS AND SHAREHOLDERS OF TERMINIX AND RENTOKIL ARE URGED TO
READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT/PROSPECTUS AND SHAREHOLDER PROXY CIRCULAR, AS APPLICABLE,
AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC OR APPLICABLE SECURITIES REGULATORS IN
THE UNITED KINGDOM, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, IN CONNECTION WITH THE PROPOSED
TRANSACTION WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT TERMINIX, RENTOKIL,
THE PROPOSED TRANSACTION AND RELATED MATTERS. The registration statement and proxy statement/prospectus and other documents filed
by Rentokil and Terminix with the SEC, when filed, will be available free of charge at the SEC’s website at www.sec.gov. In addition, investors and
shareholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed with the SEC by Terminix online at
investors.terminix.com, upon written request delivered to Terminix at 150 Peabody Pl., Memphis, TN 38103, USA, Attention: Corporate Secretary,
or by calling Terminix’s Corporate Secretary’s Office by telephone at +1 901-597-1400 or by email at deidre.richardson@terminix.com, and will
be able to obtain free copies of the registration statement, proxy statement/prospectus, shareholder proxy circular and other documents which
will be filed with the SEC and applicable securities regulators in the United Kingdom by Rentokil online at https://www.rentokil-initial.com, upon
written request delivered to Rentokil at Compass House, Manor Royal, Crawley, West Sussex, RH10 9PY, England, Attention: Katharine Rycroft, or
by calling Rentokil by telephone at +44 (0) 7811 270734 or by email at katharine.rycroft@rentokil-initial.com.
This communication is for informational purposes only and is not intended to, and shall not, constitute an offer to sell or buy or the solicitation
of an offer to sell or buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to appropriate registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be
made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.
Participants in the Solicitation of Proxies
This communication is not a solicitation of proxies in connection with the proposed transaction. However, under SEC rules, Terminix, Rentokil, and
certain of their respective directors, executive officers and other members of the management and employees may be deemed to be participants
in the solicitation of proxies in connection with the proposed transaction. Information about Terminix’s directors and executive officers may be
found on its website at corporate.terminix.com/responsibility/corporate-governance and in its 2020 Annual Report on Form 10-K filed with the
SEC on February 26, 2021, available at investors.terminix.com and www.sec.gov. Information about Rentokil’s directors and executive officers
may be found on its website at https://www.rentokil-initial.com and in its 2020 Annual Report filed with applicable securities regulators in the
United Kingdom on March 31, 2021, available on its website at https://www.rentokil-initial.com. These documents can be obtained free of charge
from the sources indicated above. Additional information regarding the interests of such potential participants in the solicitation of proxies in
connection with the proposed transaction will be included in the proxy statement/prospectus and shareholder proxy circular and other relevant
materials filed with the SEC and applicable securities regulators in the United Kingdom when they become available.
Information Regarding Forward-Looking Statements
This communication contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements
can sometimes be identified by the use of forward-looking terms such as “believes,” “expects,” “may,” “will,” “shall,” “should,” “would,” “could,”
“potential,” “seeks,” “aims,” “projects,” “predicts,” “is optimistic,” “intends,” “plans,” “estimates,” “targets,” “anticipates,” “continues” or other
comparable terms or negatives of these terms, but not all forward-looking statements include such identifying words. Forward-looking statements
are based upon current plans, estimates and expectations that are subject to risks, uncertainties and assumptions. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or
anticipated by such forward-looking statements. We can give no assurance that such plans, estimates or expectations will be achieved and
therefore, actual results may differ materially from any plans, estimates or expectations in such forward-looking statements. Important factors
that could cause actual results to differ materially from such plans, estimates or expectations include: a condition to the closing of the proposed
transaction may not be satisfied; the occurrence of any event that can give rise to termination of the proposed transaction; a regulatory approval
that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; Rentokil
is unable to achieve the synergies and value creation contemplated by the proposed transaction; Rentokil is unable to promptly and effectively
integrate Terminix’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the proposed
transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of Rentokil declines following
the proposed transaction; legal proceedings are instituted against Terminix or Rentokil; Terminix or Rentokil is unable to retain or hire key personnel;
the announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Terminix or
Rentokil or on Terminix’s or Rentokil’s operating results; evolving legal, regulatory and tax regimes; changes in economic, financial, political and
regulatory conditions, in the United Kingdom, the United States and elsewhere, and other factors that contribute to uncertainty and volatility,
natural and man-made disasters, civil unrest, pandemics (e.g., the coronavirus (COVID-19) pandemic (the “COVID-19 pandemic”)), geopolitical
uncertainty, and conditions that may result from legislative, regulatory, trade and policy changes associated with the current or subsequent
U.S. or U.K. administration; the ability of Rentokil or Terminix to successfully recover from a disaster or other business continuity problem due to
a hurricane, flood, earthquake, terrorist attack, war, pandemic, security breach, cyber-attack, power loss, telecommunications failure or other
natural or man-made event, including the ability to function remotely during long-term disruptions such as the COVID-19 pandemic; the impact
of public health crises, such as pandemics (including the COVID-19 pandemic) and epidemics and any related company or governmental policies
and actions to protect the health and safety of individuals or governmental policies or actions to maintain the functioning of national or global
economies and markets, including any quarantine, “shelter in place,” “stay at home,” workforce reduction, social distancing, shut down or similar
actions and policies; actions by third parties, including government agencies; the risk that disruptions from the proposed transaction will harm
Rentokil’s or Terminix’s business, including current plans and operations; certain restrictions during the pendency of the acquisition that may
impact Rentokil’s or Terminix’s ability to pursue certain business opportunities or strategic transactions; Rentokil’s or Terminix’s ability to meet
expectations regarding the accounting and tax treatments of the proposed transaction; the risks and uncertainties discussed in the “Risks and
Uncertainties” section in Rentokil’s reports available on the National Storage Mechanism at morningstar.co.uk/uk/NSM and on its website at
https://www.rentokil-initial.com; and the risks and uncertainties discussed in the “Risk Factors” and “Information Regarding Forward-Looking
Statements” sections in Terminix’s reports filed with the SEC. These risks, as well as other risks associated with the proposed transaction, will be
more fully discussed in the proxy statement/prospectus and shareholder proxy circular. While the list of factors presented here is, and the list of
factors to be presented in proxy statement/prospectus and shareholder proxy circular will be, considered representative, no such list should be
considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the
realization of forward-looking statements. We caution you not to place undue reliance on any of these forward-looking statements as they are
not guarantees of future performance or outcomes and that actual performance and outcomes, including, without limitation, our actual results of
operations, financial condition and liquidity, and the development of new markets or market segments in which we operate, may differ materially
from those made in or suggested by the forward-looking statements contained in this communication. Neither Rentokil nor Terminix assumes any
obligation to update or revise the information contained herein, which speaks only as of the date hereof.
|